Top Back to top

A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Study number:
2013-003831-31
Type of transplant:
 
Short title:
MK8228
Study status:
Recruiting
Deadline for data collection:
 
Study design:
Prosepctive, randomised, placebo controlled, mulit site, double blind
Primary objective:
To evaluate the efficacy of MK-8228 in the prevention of clinically significant CMV infection through Week 24 (~6 months) post-transplant following administration of MK-8228 or placebo.
Key inclusion criteria:
 
Country:
Austria
Belgium
Brazil
Canada
Finland
France
Germany
Italy
Japan
Lithuania
New Zealand
Peru
Poland
Romania
South Korea
Spain
Sweden
Turkey
United Kingdom
United States
Principal investigator:
 
Principal investigator email:
 
EBMT Study coordinator:
Sue Philpott